Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs Blog

Menu

Skip to content
  • Drug Discovery Research
  • Immunotherapy Research
  • Antibody Engineering Research

Category Archives: News

What Is the ROI of Anti-cancer Drug R&D? The Latest Research Showed that an Investment of $ 648 Million Can Generate Revenue of $ 1,658 Million

December 5, 2017Drug Discovery Research, NewsAntibody Discovery, Therapeutic Antibodybiolabs

  A new study recently calculated the development costs of 10 new anti-tumor drugs over the 10-year period between 2006 and 2015, and found that the median development time for these 10Read More…

Brentuximab Vedotin

Collaboration to Evaluate Combination of Nivolumab + Brentuximab Vedotin in Phase III Trial in Relapsed Hodgkin Lymphoma Expanded

November 22, 2017Antibody Engineering Research, NewsADC, Antibody Drug Conjugationbiolabs

“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…

30Oct/17

Chinese Scientists Discovered Strong Oncolytic Virus Synergist

October 30, 2017Immunotherapy Research, NewsCAR-T, ERAD pathway, M1, oncolytic virusbiolabs

On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…

Income and R&D expense proportion of pharmaceutical giants in 2016

Top 10 R&D Expense of Pharmaceutical Giants (i)

September 28, 2017Antibody Engineering Research, Newsantibody development, Antibody Discovery, biosimiar, Therapeutic Antibodybiolabs

Generally, when the business of a pharmaceutical giant reaches a plateau, its business volume won’t change much during this period. Instead, it will try to optimize its structure, including R&D and productionRead More…

01Sep/17

Carl June Published His Latest Paper: The Results of CAR-T Therapy Human Trials on the Treatment of Solid Tumors Shows Two Hurdles Still Need to Be Overcome!

September 1, 2017Immunotherapy Research, NewsCAR-T, CAR-T transfusion, CART-EGFRvIII, CTL019biolabs

In this month, FDA oncologic Drugs Advisory Committee agreed to the approval of Novartis’s CAR-T CTL019 therapy on a vote of 10:0 for the treatment of relapsed or refractory children and youngRead More…

16Aug/17

Revelation! CAR-T Has Its “Eyes” on Solid Tumor and the Treatment of That Would Be Possible

August 16, 2017Immunotherapy Research, Newscancer, CAR-T, immunotherapy, tumorbiolabs

Immunotherapy has become a new hope against cancer. CAR-T cell therapy is achieved by using genetic engineering method to express chimeric antigen receptors on T cells obtained from donner patients. These chimericRead More…

24Jul/17

The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!

July 24, 2017Immunotherapy Research, NewsCAR-T, FDA, immunotherapy drug, Novartisbiolabs

Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…

22Jun/17

Will the First CAR-T Therapy Be Approved on July 12? —Novartis CTL019

June 22, 2017Immunotherapy Research, NewsCAR-T, CAR-T therapy, CTL019, Novartisbiolabs

On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…

16Jun/17

Best Selling Anti-tumor Drugs in the Next 5 Years

June 16, 2017Antibody Engineering Research, Newsanti-tumor drug, Antibody, monoclonal antibody, Therapeutic Antibodybiolabs

According to the Journal of the American Medical Association, there were 15.4 million cancer patients worldwide in 2013. Among them, the cancer mortality rate in developing countries was higher than that ofRead More…

15May/17

Prediction of the Top 10 Best Selling Drugs in 2017 (II)

May 15, 2017Antibody Engineering Research, Newsrecombinant antibody, Therapeutic Antibodybiolabs

Let’s see the other five Top 10 Best Selling drugs ranking from 6th to 10th. 6. Trastuzumab Trastuzumab (trade name: Herceptin) is a humanized monoclonal antibody. It targets HER2, blocks the functionRead More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »

Categories

  • Antibody Engineering Research
  • Biological Knowledge
  • Drug Discovery Research
  • Immunotherapy Research
  • News

Recent Posts

  • Multivalent Single Domain Antibodies Help Block SARS-CoV-2 Infection and Suppress Mutational Escape
  • Nat Methods: How to Enhance the Effect of T Cell Therapy?
  • New TCR Therapy—Tebentafusp
  • eLife: The New Anticancer Mechanism of T Cells
  • The Discoverers of Hepatitis C Virus Won the 2020 Nobel Prize in Physiology or Medicine

Archives

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828

Copyright © Creative Biolabs Blog
Powered by WordPress , Designed and Developed by templatesnext